Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

250.00DKK
10:59am EDT
Change (% chg)

kr.-2.50 (-0.99%)
Prev Close
kr.252.50
Open
kr.250.00
Day's High
kr.252.00
Day's Low
kr.246.00
Volume
113,583
Avg. Vol
152,175
52-wk High
kr.361.00
52-wk Low
kr.197.00

Latest Key Developments (Source: Significant Developments)

Bavarian Nordic: Janssen completes submission for EUAL for Ebola vaccine regimen to WHO
Tuesday, 13 Sep 2016 05:44am EDT 

Bavarian Nordic A/S : Said on Monday its partner, Janssen had completed submission for Emergency Use Assessment and Listing (EUAL) for its Ebola vaccine regimen to World Health Organization . EUAL is special procedure that can be implemented when there is outbreak of disease with high rates of morbidity or mortality and lack of treatment or prevention options . Said preparations also underway to initiate first-in-human study for multivalent vaccine regimen to combat Ebola, Sudan and Marburg viruses .Janssen's investigational preventive Ebola prime-boost vaccine regimen includes Bavarian Nordic's MVA-BN Filo vaccine.  Full Article

Bavarian Nordic Q2 EBIT swings to loss DKK 54.0 million
Wednesday, 17 Aug 2016 01:53am EDT 

Bavarian Nordic A/S : H1 revenue 139 million Danish crowns ($21 million) versus 624 million crowns year ago . Q2 revenue 116.6 million crowns versus 389.1 million crowns year ago . Q2 EBIT loss 54.0 million crowns versus profit 125.0 million crowns year ago .Maintains its financial expectations for 2016.  Full Article

Bavarian Nordic: Expansion of IMVAMUNE orders from Canada
Wednesday, 15 Jun 2016 09:04am EDT 

Bavarian Nordic A/S : Announces expansion of IMVAMUNE orders from Canadian government . Canadian government exercised option for supply of 171,000 doses of IMVAMUNE smallpox vaccine to national stockpile at total value of $7.7 million .Says contents of this announcement do not affect company's expectations for financial results for 2016.  Full Article

Bavarian Nordic Q1 EBIT loss increases to DKK 153 million
Friday, 13 May 2016 01:47am EDT 

Bavarian Nordic A/S : Q1 revenue 23 million Danish crowns ($3.52 million) versus 235 million crowns year ago . Q1 EBIT loss 153 million crowns versus loss 40 million crowns year ago .Maintains its financial expectations for 2016.  Full Article

Bavarian Nordic A/S: Positive data for Ebola vaccine regimen
Monday, 18 Apr 2016 06:00pm EDT 

Bavarian Nordic A/S:Results of Phase 1 study of a preventive Ebola vaccine regimen suggest that regimen was well-tolerated by healthy volunteers and did not result in any vaccine-related serious adverse events.Study tested vaccine regimen containing two components, of which one was based on MVA-BN technology from Bavarian Nordic.Confirmed data from a Phase 1 study of a preventive Ebola vaccine regimen have been published in The Journal of the American Medical Association.  Full Article

Bavarian Nordic completes a private placement at market price
Monday, 18 Apr 2016 02:03am EDT 

Bavarian Nordic A/S:Completes a private placement at market price.Says subscription price is 240 Danish crowns per share.Raises gross proceeds in private placement of about 665 million crowns.Raises expectations to FY 2016 year-end cash preparedness to level of 1.90 billion crowns from 1.30 billion crowns.  Full Article

Bavarian Nordic A/S to raise up to 665 million crowns in private placement
Thursday, 14 Apr 2016 01:13am EDT 

Bavarian Nordic A/S:Resolved to launch an offering of up to 2.8 million shares.Offer price of 240 Danish crowns per share has been determined through accelerated bookbuilding process.To raise gross proceeds of up to about 665 million Danish crowns.Said the offering represents up to 9.87 percent of Bavarian Nordic's registered share capital.Expects to use proceeds to accelerate commercial vaccine pipeline.Maintains 2016 financial outlook - revenue at level of 1.00 billion crowns and a break-even result before interest and tax (EBIT).  Full Article

Bavarian Nordic A/S gives FY 2016 revenue and EBIT guidance
Monday, 7 Mar 2016 06:50am EST 

Bavarian Nordic A/S:In FY 2016, expects revenue at level of 1,000 million Danish crowns.Sees a break-even result before interest and tax (EBIT) in FY 2016.  Full Article

Bavarian Nordic enters research collaboration to develop MRSA vaccine
Thursday, 4 Feb 2016 01:31am EST 

Bavarian Nordic A/S:‍Has entered into a joint collaboration with Evaxion Biotech and Technical University of Denmark for development of an MVA-BN-based vaccine against MRSA​.‍Intends to engineer and produce a recombinant MVA-BN-based vaccine candidate​.‍If proven safe and efficacious, human trials could occur in 2019​.‍Project has received initial funding from Innovation Fund Denmark in amount of 17 million Danish crowns.  Full Article

Bavarian Nordic files for U.S. IPO of up to $86.3 mln - SEC filing
Monday, 4 Jan 2016 11:55am EST 

Bavarian Nordic A/S:Files for U.S. IPO of up to $86.3 million - SEC filing.Says it has applied to list its ads on NASDAQ under the symbol "bavn".Cowen and co, Piper Jaffray and nomura are underwriters to IPO.IPO size estimated solely for purpose of calculating the registration fee.  Full Article

BRIEF-Bavarian Nordic names Christopher Heery Chief Medical Officer

* Most recently, Dr. Heery was Director of Clinical Trials Group of Laboratory of Tumor Immunology and Biology at National Cancer Institute Source text for Eikon: Further company coverage: (Gdynia Newsroom)